Salarius Pharmaceuticals Renames to Decoy Therapeutics, Ticker Changes to DCOY

Salarius Pharmaceuticals announced that in connection with its recent combination with Decoy Therapeutics, the Company intends to change its corporate name to Decoy Therapeutics Inc. and its NASDAQ ticker symbol to DCOY. The planned name and ticker change mark a pivotal step in the Company's transformation into a platform-driven biotechnology company focused on novel peptide-conjugate therapeutics with applications across viral diseases and oncology. The Company expects the name and ticker symbol change to become effective in early January 2026. The Company will continue to trade under the existing symbol SLRX until the effective date. The Company's transfer agent will remain unchanged. Stockholder approval was not required to take any specific action with respect to the corporate name change or new ticker symbol. The corporate name change and new ticker symbol will not impact the Company's operations. As previously announced Decoy's senior management team joined by Salarius's finance team will lead the new Company's operations. Looking ahead, the Company plans to prioritize: Advancing lead antiviral programs toward regulatory readiness; Expanding discovery and preclinical validation across multiple platforms; Leveraging AI-enabled computational infrastructure to accelerate candidate selection; Pursuing strategic collaborations with big pharma, technology leaders, and academic institutions; Strengthening the Company's capital structure and investor visibility. The Company believes this execution-focused approach positions Decoy Therapeutics to generate multiple shots on goal while retaining upside through partnerships and non-dilutive funding sources